CriticalTricyclic antidepressants (TCA)×Prokinetic, 5-HT4 serotonin receptor agonist (withdrawn EU/US)
Updated · Methodology
Mechanism
Both drugs prolong the QT interval on the electrocardiogram, and together they raise the risk of dangerous rhythm disorders. The Spanish amitriptyline summary of product characteristics (SmPC) names cisapride among QT-prolonging drugs that can increase the likelihood of ventricular arrhythmias when taken with tricyclic antidepressants (amitriptyline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Amitriptyline itself commonly prolongs the QT interval and the QRS complex and, very rarely, causes torsade de pointes (amitriptyline SmPC, AEMPS). The US Food and Drug Administration (FDA) amitriptyline label contraindicates the combination because of possible QT prolongation and a higher risk of arrhythmia. Neither the Spanish nor the US document says whether amitriptyline changes cisapride blood levels.
Symptoms
QT prolongation itself causes no symptoms and shows only on the electrocardiogram (ECG). Ventricular arrhythmias, including torsade de pointes, cause sudden strong palpitations, dizziness and fainting, and a long episode can turn into ventricular fibrillation and cardiac arrest. Amitriptyline alone very commonly causes palpitations and a fast heart rate. Atrioventricular block and bundle branch block are common and arrhythmia is rare, but at high doses arrhythmias and severe low blood pressure are likely (amitriptyline summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The risk of arrhythmia is higher with marked bradycardia, decompensated heart failure, low or high blood potassium and low blood magnesium (amitriptyline SmPC, AEMPS).
Management
The combination is contraindicated. The US Food and Drug Administration (FDA) amitriptyline label says not to give amitriptyline with cisapride because of possible QT prolongation and a higher risk of arrhythmia (amitriptyline FDA label). The Spanish amitriptyline summary of product characteristics (SmPC) lists QT-prolonging drugs, cisapride among them, under combinations not recommended with tricyclic antidepressants (amitriptyline SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Cisapride is not in the Spanish medicines register CIMA. If a person still takes cisapride obtained in another country, do not give amitriptyline with it (amitriptyline FDA label). Amitriptyline is contraindicated in any degree of heart block, rhythm disorders, coronary insufficiency and recent myocardial infarction (amitriptyline SmPC, AEMPS). Use it with caution in marked bradycardia, in decompensated heart failure, with other QT-prolonging drugs and with diuretics that lower potassium, such as furosemide (amitriptyline SmPC, AEMPS). Watch people with cardiovascular disorders closely while they take amitriptyline (amitriptyline FDA label).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Amitriptyline hydrochloride tablets (amitriptyline) prescribing information (2026)– FDA label, Sun Pharmaceutical Industries, DailyMed setid 4e520c63-1cf6-40f6-a51c-3f9b0e181342, revised 09/2026, Contraindications, Warnings (Serotonin Syndrome) and PRECAUTIONS: Drug Interactions (Drugs Metabolized by P450 2D6)
- AEMPS: Ficha técnica: Amitriptilina, Tryptizol 25 mg (nº registro 37130), secciones 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 37130, revisión 01/2025, secciones 4.4 y 4.5